|
Real-time Estimate
Cboe BZX
15:15:54 2026-11-03 EST
|
5-day change | 1st Jan Change | ||
| 84.94 USD | +0.22% |
|
+2.49% | +7.33% |
| 10-19 | Solventum Receives FDA Clearance for Combined Use of Wound Care Technologies | MT |
| 10-19 | Solventum Secures FDA Clearance for Combined Wound Care Technologies | DJ |
Company Valuation: Solventum Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 11,412 | 13,744 | 14,426 | - | - |
| Change | - | 20.43% | 4.97% | - | - |
| Enterprise Value (EV) 1 | 18,660 | 17,901 | 19,303 | 18,701 | 17,938 |
| Change | - | -4.07% | 7.83% | -3.12% | -4.08% |
| P/E | 23.9x | 8.92x | 49.7x | 22.2x | 17.1x |
| PBR | 3.86x | 2.72x | 3.03x | 2.72x | 2.37x |
| PEG | - | 0x | -0.6x | 0x | 0.6x |
| Capitalization / Revenue | 1.38x | 1.65x | 1.75x | 1.69x | 1.63x |
| EV / Revenue | 2.26x | 2.15x | 2.35x | 2.19x | 2.03x |
| EV / EBITDA | 9.25x | 9.49x | 9.48x | 9.12x | 8.27x |
| EV / EBIT | 10.3x | 10.5x | 10.4x | 9.99x | 8.91x |
| EV / FCF | 23.2x | -1,790x | 64.8x | 24.8x | 20.3x |
| FCF Yield | 4.31% | -0.06% | 1.54% | 4.03% | 4.93% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | 2.76 | 8.88 | 1.704 | 3.814 | 4.965 |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | 8,254 | 8,325 | 8,226 | 8,520 | 8,856 |
| EBITDA 1 | 2,018 | 1,886 | 2,036 | 2,050 | 2,170 |
| EBIT 1 | 1,812 | 1,709 | 1,852 | 1,873 | 2,013 |
| Net income 1 | 479 | 1,556 | 300.2 | 651.9 | 850.3 |
| Net Debt 1 | 7,248 | 4,157 | 4,877 | 4,275 | 3,511 |
| Reference price 2 | 66.06 | 79.24 | 84.75 | 84.75 | 84.75 |
| Nbr of stocks (in thousands) | 172,754 | 173,448 | 170,224 | - | - |
| Announcement Date | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 49.74x | 2.35x | 9.48x | -.--% | 14.43B | |
| 36.44x | 4.29x | 16.1x | 2.35% | 191B | |
| 21.35x | 3.66x | 13.1x | 2.86% | 122B | |
| 26.33x | 4.72x | 16.13x | 1.18% | 117B | |
| 32.8x | 3.15x | 12.71x | 2.17% | 96.21B | |
| 17.92x | 0.21x | 13.38x | 0.7% | 64.47B | |
| 29.83x | 7.43x | 18.98x | 1.36% | 52.51B | |
| 40.48x | 3.63x | 12.36x | 2.1% | 54.1B | |
| 44.66x | 11.28x | 31.6x | -.--% | 52.91B | |
| 43.69x | 3.46x | 12.85x | 0.5% | 35.65B | |
| Average | 34.33x | 4.42x | 15.67x | 1.32% | 79.92B | |
| Weighted average by Cap. | 31.69x | 4.34x | 15.72x | 1.74% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SOLV Stock
- Valuation Solventum Corporation
Select your edition
All financial news and data tailored to specific country editions
